Abstract
The main therapy for primary breast cancer is not surgery, but a systemic therapy involving administration of cytotoxic chemotherapy or the use of ablative or additive endocrine therapy to control disseminated micrometastasis. The results of randomized trials and meta-analysis show that CMF, the standard adjuvant chemotherapy, is effective regardless of axillar lymph node involvement or menopausal status. Effectiveness of adjuvant chemotherapy with an anthracyclin-based regimen remains controversial. The trial by CUBC and NSAS-BC comparing UFT, widely used in the management of patients with breast cancer in Japan, with CMF is on-going.
Publication types
-
English Abstract
-
Meta-Analysis
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Cisplatin / administration & dosage
-
Drug Combinations
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Lymphatic Metastasis
-
Methotrexate / administration & dosage
-
Mitomycin / administration & dosage
-
Randomized Controlled Trials as Topic
-
Tamoxifen / administration & dosage
-
Tegafur / administration & dosage
-
Uracil / administration & dosage
Substances
-
Drug Combinations
-
UFT(R) drug
-
Tamoxifen
-
Tegafur
-
Mitomycin
-
Uracil
-
Cisplatin
-
Fluorouracil
-
Methotrexate